Potent and Efficacious Inhibition of CXCR2 Signaling by Biparatopic Nanobodies Combining Two Distinct Modes of Action-Reference-Cited by-同舟云学术

Potent and Efficacious Inhibition of CXCR2 Signaling by Biparatopic Nanobodies Combining Two Distinct Modes of Action

Published:2014-12-02 Issue:2 Volume:87 Page:251-262
ISSN:0026-895X
Container-title:Molecular Pharmacology
language:en
Short-container-title:Mol Pharmacol

Author:

Bradley M. E.,Dombrecht B.,Manini J.,Willis J.,Vlerick D.,De Taeye S.,Van den Heede K.,Roobrouck A.,Grot E.,Kent T. C.,Laeremans T.,Steffensen S.,Van Heeke G.,Brown Z.,Charlton S. J.,Cromie K. D.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference31 articles.

1. Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor

2. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

3. SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor

4. CXCR2 antagonists for the treatment of pulmonary disease

5. Asymmetric conformational changes in a GPCR dimer controlled by G-proteins

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review;Cancers;2024-07-27

2. Highly biased agonism for GPCR ligands via nanobody tethering;Nature Communications;2024-06-01

3. Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions;mAbs;2024-04-26

4. vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma as a Target;Antibodies;2024-03-18

5. Biparatopic antibodies: therapeutic applications and prospects;mAbs;2024-03-04